Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine plus irinotecan with or without apatinib as second-line treatment for advanced colorectal cancer
ChiCTR1800019065Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Nov 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Rivoceranib, capecitabine and irinotecan in colorectal cancer (CRC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: progression-free survival. Started Nov 2018; status: recruiting.
02
Drugs
Rivoceranibcapecitabineirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR1800019065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019065.